Kaarta is the innovator of real-time mobile 3D reality capture, mapping complex environments with unprecedented speed, fidelity, and ease. It works without external signal infrastructures such as GPS or Wi-Fi. Kaarta’s patent-pending technology, rooted in advanced robotics, accurately transforms the real world into multi-dimensional 3D digital models, streamlining workflow, reducing time, lowering cost, and providing a new level of understanding of spaces for humans and autonomous machines alike. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Neuronetics is a medical technology company. They develop non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. They specialize in providing therapy for mental health.
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.
RainDance Technologies develops medical technology solutions. Their droplet technology to research in areas including non-invasive liquid biopsy. They provide molecules, single-cell analyzes, reaction methodology, cancer research, mutation detection, and diagnostics services.
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products. The company was founded in 2011 and is located at Wayne, PA, USA.
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
NovaSom, Inc. is a privately held diagnostic-service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of obstructive sleep apnea (OSA). The company is a Medicare-approved Independent Diagnostic Testing Facility (IDTF) and is fully accredited as both an Ambulatory Care Sleep Diagnostic Center and as a Telehealth provider by The Joint Commission. The home testing system manufactured and distributed by NovaSom has FDA clearance for the diagnostic evaluation of OSA in adults. NovaSom has integrated their home sleep testing system into a cloud-based, collaborative patient management platform for physicians and payers. It is based in Glen Burnie, Maryland, the company was incorporated in 1992.
Neuronetics is a medical technology company. They develop non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. They specialize in providing therapy for mental health.
RainDance Technologies develops medical technology solutions. Their droplet technology to research in areas including non-invasive liquid biopsy. They provide molecules, single-cell analyzes, reaction methodology, cancer research, mutation detection, and diagnostics services.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye.
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
BioLeap is an emerging drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap's design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap's technology provides a viable alternative to high-throughput screening and traditional shape-based âdockingâ approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.
Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.
Neuronetics is a medical technology company. They develop non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. They specialize in providing therapy for mental health.
Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for its product candidates in the U.S. and territories throughout the world.
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
EKR Therapeutics, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing prescription products and oncology supportive care. It focuses on various areas, including oral mucositis, stomatitis, dry mouth/xerostomia, nutritional issues, cachexia, skin reactions, bone marrow depression, bone complications, acute and chronic pain, nausea, vomiting, and diarrhea. The company was founded in 2005 and is based in Bedminster, New Jersey.
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.
Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases involving the alternative complement cascade. The company was founded in 2005 and is based in New Haven, Connecticut.
EKR Therapeutics, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing prescription products and oncology supportive care. It focuses on various areas, including oral mucositis, stomatitis, dry mouth/xerostomia, nutritional issues, cachexia, skin reactions, bone marrow depression, bone complications, acute and chronic pain, nausea, vomiting, and diarrhea. The company was founded in 2005 and is based in Bedminster, New Jersey.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
NitricBio is a mid-stage specialty pharmaceutical company focused on the dermatology and podiatry markets, with two unique drug delivery technologies. The first technology involves the development and commercialization of topical nitric oxide gas. Nitric oxide has both direct and regulatory actions with known anti-infective and anti-inflammatory properties. The company's current focus is on the development of a treatment for moderate-to-severe tinea pedis (athlete's foot), which is currently in late Phase 2 clinical trials.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.
Neotropix, Inc., a biotechnology company, develops and commercializes systemically deliverable oncolytic viruses for the treatment of neuroendocrine cancers. It develops NTX010, a naturally-occurring virus that attacks and kills neuroendocrine cancers, such as small cell lung cancer, small cell carcinomas originating in other organs, carcinoid, neuroblastoma, and certain other neuroendocrine cancers. The company was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Nucleonics
Series B in 2004
Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.
Medmark is a healthcare center. They provide outpatient medication-assisted treatment for opioid addiction, utilizing methadone and buprenorphine. Their services include buprenorphine maintenance, methadone maintenance, addiction education, medical screenings, case management, discharge planning, and guest medication services.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.